Business Context and Reporting Period
Mesa Laboratories, Inc. develops and sells quality-control products through its Biological Indicators, Instruments, and Continuous Monitoring divisions. The filing is a Form 10-Q for the quarter and nine months ended December 31, 2013, with fiscal year ending March 31, 2014. The request metadata identifies “2012 Q3,” but the filing text clearly reports 2013 results and comparisons with December 31, 2012.
Financial Results and Position
| Metric | Three months ended Dec. 31, 2013 | Three months ended Dec. 31, 2012 | Nine months ended Dec. 31, 2013 | Nine months ended Dec. 31, 2012 |
|---|---|---|---|---|
| Revenue | $13.116 million | $11.361 million | $37.010 million | $33.627 million |
| Gross profit | $7.706 million | $6.947 million | $22.103 million | $20.651 million |
| Gross margin | 59% | 61% | 60% | 61% |
| Operating income | $2.806 million | $2.464 million | $8.364 million | $9.173 million |
| Net income | $1.746 million | $1.543 million | $5.538 million | $5.891 million |
| Diluted EPS | $0.48 | $0.44 | $1.54 | $1.67 |
- Quarterly revenue increased 15%, while quarterly net income increased 13%; nine-month revenue increased 10%, but net income declined 6%.
- Quarterly operating expenses increased 9% to $4.900 million. Nine-month operating expenses increased 20% to $13.739 million.
- At December 31, 2013, cash and cash equivalents were $2.160 million, working capital was $9.817 million, and total assets were $92.555 million.
- Long-term debt was $16.000 million, compared with $4.000 million at March 31, 2013. The company had $4.000 million of unused revolving-credit capacity and was in compliance with its debt covenants.
- Nine-month operating cash flow was $9.474 million, compared with $8.451 million in the prior-year period. Investing cash outflow was $22.905 million, principally for acquisitions, and financing cash inflow was $11.585 million.
- Cash declined by $1.846 million during the nine months, ending at $2.160 million.
- The company declared a quarterly dividend of $0.15 per share payable March 17, 2014.
Material Changes Versus the Prior Comparable Period
- Revenue growth reflected organic growth in Biological Indicators and Instruments, the July 2013 SureTorque acquisition, and the November 2013 acquisitions of TempSys and Amega.
- Continuous Monitoring generated $1.361 million of revenue in the quarter and nine-month period following the TempSys and Amega acquisitions; it had no comparable reported revenue in 2012.
- Quarterly gross margin declined two percentage points, primarily because of acquisition-related integration costs and manufacturing costs associated with moving SureTorque operations. Continuous Monitoring also had a 44% gross margin, which management said was reduced by integration activities.
- Management expects Continuous Monitoring integration activities to be substantially completed during the second half of the year ending March 31, 2015, with margins expected to move closer to historical levels.
- Nine-month general and administrative expense included a $1.106 million accrual for estimated prior-period state sales-tax exposure. The company stated that the ultimate liability may change.
- Operating income and net income for the nine-month period declined despite higher revenue, reflecting higher selling, general and administrative, and research and development expenses.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
- The filing provides no formal numerical revenue or earnings guidance. Management expects Biological Indicators markets to remain strong and states that demand for Instruments and newly acquired Continuous Monitoring systems remains strong, while acknowledging economic uncertainty and discretionary customer capital spending.
- Management anticipates an effective tax rate of approximately 36.3% and expects SOX compliance costs to remain relatively flat for fiscal 2014.
- Management is pursuing organic growth, further acquisitions, infrastructure improvements, and research and development projects that may produce new products.
- The Amega acquisition involved $11.268 million of cash consideration, a $1.000 million holdback, and recorded contingent consideration of $0.500 million. Potential additional Amega consideration ranges from $0 to $10.000 million, payable in fiscal 2017 depending on revenue performance.
- TempSys was acquired for $9.826 million. The acquisitions were financed partly with $18.000 million of revolving debt; the company repaid $2.000 million during the quarter and an additional $1.000 million in January 2014.
- The company recorded a $0.468 million pretax gain on the August 2013 sale of the NuSonics product line.
- Other contingencies include Bios contingent consideration with a potential undiscounted payment of up to $6.710 million, a $1.000 million Amega holdback, and a $0.100 million SureTorque holdback.
- Key risks include economic weakness affecting discretionary instrument purchases, acquisition integration, margin pressure, debt and covenant requirements, uncertain state sales-tax liabilities, supply-chain or operating disruptions, cyberattacks, catastrophic events, and changes in customer spending.
- Management reported effective disclosure controls and internal control over financial reporting as of December 31, 2013, with no significant changes in internal controls during the nine-month period.
Investor Verification Checklist
- Verify the reporting-period discrepancy between the request metadata and the filing’s stated December 31, 2013 period.
- Assess whether acquisition-driven revenue growth translates into sustainable organic growth and improved Continuous Monitoring margins.
- Review the $16.000 million debt balance, February 2015 maturity of the revolving facility, available capacity, interest rates, and covenant headroom.
- Monitor the resolution and potential changes to the $1.106 million state sales-tax accrual.
- Evaluate the range and timing of Amega and Bios contingent consideration and related effects on future cash flow and earnings.
- Reconcile reported results with the filing’s pro forma acquisition information, which presents nine-month 2013 pro forma revenue of $43.559 million and net income of $6.849 million.